Focus on management of pacemaker and ICD advisories, recalls, and alerts
- PMID: 16939672
- DOI: 10.1007/s11936-006-0038-2
Focus on management of pacemaker and ICD advisories, recalls, and alerts
Abstract
Because the number of implantable cardiac devices has dramatically increased, device alerts and advisories have become a part of routine clinical practice. When a physician is faced with the management of a patient with an implanted device that has been the subject of a recall or advisory, the major concern facing the clinician is how to manage the patient and whether the device needs to be replaced. A rational approach to evaluating patients with a device or lead that is the subject of a US Food and Drug Administration advisory requires evaluating the competing risks of elective device or lead replacement versus keeping the recalled device or lead in place. It is important to keep in mind that the risks of replacing devices are not insignificant and may outweigh the risks of death from device malfunction. Ultimately, this decision should be based on the estimated device (lead) malfunction rate, device (lead) dependency, and an individual center's procedural risk for complications from generator (lead) removal, and should also factor in patient preferences.
Similar articles
-
Recalls and safety alerts involving pacemakers and implantable cardioverter-defibrillator generators.JAMA. 2001 Aug 15;286(7):793-9. doi: 10.1001/jama.286.7.793. JAMA. 2001. PMID: 11497532
-
The effect of device advisories on implantable cardioverter-defibrillator therapy.Curr Cardiol Rep. 2010 Sep;12(5):361-6. doi: 10.1007/s11886-010-0124-7. Curr Cardiol Rep. 2010. PMID: 20512632
-
Physician management of pacemaker and implantable cardioverter defibrillator advisories.Pacing Clin Electrophysiol. 2004 Apr;27(4):437-42. doi: 10.1111/j.1540-8159.2004.00460.x. Pacing Clin Electrophysiol. 2004. PMID: 15078394 Clinical Trial.
-
Should recent defibrillator and lead advisories affect decisions to refer patients for implantable cardioverter-defibrillator therapy?Curr Opin Cardiol. 2010 Jan;25(1):23-8. doi: 10.1097/HCO.0b013e328333d375. Curr Opin Cardiol. 2010. PMID: 19907318 Review.
-
[Postmarketing surveillance in patients with cardiac pace-makers or automatic implantable defibrillators].Ann Cardiol Angeiol (Paris). 2005 Jan;54(1):38-43. doi: 10.1016/j.ancard.2004.11.004. Ann Cardiol Angeiol (Paris). 2005. PMID: 15702910 Review. French.
Cited by
-
Contributions of remote monitoring to the follow-up of implantable cardioverter-defibrillator leads under advisory.Eur Heart J. 2010 Sep;31(18):2246-52. doi: 10.1093/eurheartj/ehq203. Epub 2010 Jun 30. Eur Heart J. 2010. PMID: 20591841 Free PMC article. Clinical Trial.
References
LinkOut - more resources
Full Text Sources